JP2003526673A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526673A5
JP2003526673A5 JP2001566681A JP2001566681A JP2003526673A5 JP 2003526673 A5 JP2003526673 A5 JP 2003526673A5 JP 2001566681 A JP2001566681 A JP 2001566681A JP 2001566681 A JP2001566681 A JP 2001566681A JP 2003526673 A5 JP2003526673 A5 JP 2003526673A5
Authority
JP
Japan
Prior art keywords
composition
papillomavirus
pyrimidine
iss
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001566681A
Other languages
English (en)
Other versions
JP2003526673A (ja
Filing date
Publication date
Priority claimed from US09/802,445 external-priority patent/US20020107212A1/en
Application filed filed Critical
Publication of JP2003526673A publication Critical patent/JP2003526673A/ja
Publication of JP2003526673A5 publication Critical patent/JP2003526673A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 免疫刺激性配列(ISS)を含むポリヌクレオチドを含む、乳頭腫ウイルスに暴露された個体における乳頭腫ウイルス感染の症状の予防のための医薬組成物であって、上記ISSが配列5’−C,G,ピリミジン,ピリミジン,C,G−3’を含み、乳頭腫ウイルス抗原が前記組成物の投与と共に投与されず、そして前記組成物が乳頭腫ウイルス感染の症状を予防するのに十分な量で投与される前記組成物
【請求項2】 前記ISSが配列5’−プリン,プリン,C,G,ピリミジン,ピリミジン,C,G−3’を含む、請求項1に記載の組成物
【請求項3】 前記ISSが5’−AACGTTCG−3’、及び5’−GACGTTCG−3’から成る群から選ばれる配列を含む、請求項2に記載の組成物
【請求項4】 前記ISSが配列5’−TGACTGTGAACGTTCGAGATGA−3’(配列番号:1)を含む、請求項1に記載の組成物
【請求項5】 前記個体が哺乳類である、請求項1に記載の組成物
【請求項6】 投与が露出の部位である、請求項1に記載の組成物
【請求項7】 前記乳頭腫ウイルスがヒト乳頭腫ウイルス(HPV)である、請求項1に記載の組成物
【請求項8】 前記乳頭腫ウイルスが動物乳頭腫ウイルスである、請求項1に記載の組成物
【請求項9】 免疫刺激性配列(ISS)を含むポリヌクレオチドを含む、乳頭腫ウイルスに感染した個体における乳頭腫ウイルス感染の症状の重篤さの軽減のための医薬組成物であって、上記ISSが配列5’−C,G,ピリミジン,ピリミジン,C,G−3’を含み、乳頭腫ウイルス抗原が前記組成物の投与と共に投与されず、そして前記組成物が乳頭腫ウイルス感染の症状の重篤さを軽減させるのに十分な量で投与される前記組成物
【請求項10】 上記ISSが配列5’−プリン,プリン,C,G,ピリミジン,ピリミジン,C,G−3’を含む、請求項9に記載の組成物
【請求項11】 上記ISSが5’−AACGTTCG−3’及び5’−GACGTTCG−3’から成る群から選ばれる配列を含む、請求項10に記載の組成物
【請求項12】 上記ISSが配列5’−TGACTGTGAACGTTCGAGATGA−3’(配列ID番号:1)を含む、請求項9に記載の組成物
【請求項13】 上記個体が哺乳類である、請求項9に記載の組成物
【請求項14】 投与が感染部位である、請求項9に記載の組成物
【請求項15】 上記乳頭腫ウイルスがヒト乳頭腫ウイルス(HPV)である、請求項9に記載の組成物
【請求項16】 上記乳頭腫ウイルスが動物乳頭腫ウイルスである、請求項9に記載の方法。
【請求項17】 免疫刺激性配列(ISS)を含むポリヌクレオチドを含む組成物を含む、乳頭腫ウイルスに感染した、暴露された又は暴露されるおそれのある個体における乳頭腫ウイルス感染の症状の治療における使用のためのキットであって、上記ISSが配列5’−C,G,ピリミジン,ピリミジン,C,G−3’を含み、前記キットが乳頭腫ウイルス抗原を含まず、そして上記キットが乳頭腫ウイルスに感染した、暴露された又は暴露されるおそれのある個体に前記組成物を投与するための教示を含むキット。
【請求項18】 上記ISSが配列5’−プリン,プリン,C,G,ピリミジン,ピリミジン,C,G−3’を含む、請求項17に記載のキット。
【請求項19】 上記ISSが5’−AACGTTCG−3’及び5’−GACGTTCG−3’から成る群から選ばれる配列を含む、請求項18に記載のキット。
【請求項20】 上記ISSが配列5’−TGACTGTGAACGTTCGAGATGA−3’(配列ID番号:1)を含む、請求項17に記載のキット。
【請求項21】 上記乳頭腫ウイルスがヒト乳頭腫ウイルス(HPV)である、請求項17に記載のキット。
【請求項22】 上記乳頭腫ウイルスが動物乳頭腫ウイルスである、請求項17に記載のキット。
JP2001566681A 2000-03-10 2001-03-12 免疫調節性ポリヌクレオチド配列を用いた乳頭腫ウイルス感染の軽減方法 Pending JP2003526673A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18826500P 2000-03-10 2000-03-10
US60/188,265 2000-03-10
US09/802,445 US20020107212A1 (en) 2000-03-10 2001-03-09 Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US09/802,445 2001-03-09
PCT/US2001/007842 WO2001068117A2 (en) 2000-03-10 2001-03-12 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections

Publications (2)

Publication Number Publication Date
JP2003526673A JP2003526673A (ja) 2003-09-09
JP2003526673A5 true JP2003526673A5 (ja) 2008-05-01

Family

ID=26883889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001566681A Pending JP2003526673A (ja) 2000-03-10 2001-03-12 免疫調節性ポリヌクレオチド配列を用いた乳頭腫ウイルス感染の軽減方法

Country Status (8)

Country Link
US (3) US20020107212A1 (ja)
EP (1) EP1261353B1 (ja)
JP (1) JP2003526673A (ja)
AT (1) ATE475423T1 (ja)
AU (2) AU2001243588B2 (ja)
CA (1) CA2402014A1 (ja)
DE (1) DE60142683D1 (ja)
WO (1) WO2001068117A2 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2396871A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
EP1404873B1 (en) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003012061A2 (en) * 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
EP1420829A4 (en) * 2001-08-07 2006-05-17 Dynavax Tech Corp IMMUNOMODULATING COMPOSITIONS, FORMULATIONS AND METHOD FOR THEIR USE
EP1414490A1 (en) * 2001-08-10 2004-05-06 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
CN101160399A (zh) 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003304107B2 (en) 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2003297483B2 (en) 2002-12-23 2010-11-18 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2600036A1 (en) 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
DK2269622T3 (en) 2005-07-01 2014-03-24 Index Pharmaceuticals Ab CPG OLIGONUCLEOTIDES USED TO INCREASE STEROID ACTIVITY OF A STEROID DEPENDENT PATIENT
ES2435531T3 (es) 2005-07-01 2013-12-20 Index Pharmaceuticals Ab Modulación de la capacidad de respuesta a los esteroides
US8895522B2 (en) 2005-10-28 2014-11-25 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5616461A (en) * 1992-05-14 1997-04-01 Dana-Farber Cancer Institute Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1005368B1 (en) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ES2326848T3 (es) * 1997-06-06 2009-10-20 The Regents Of The University Of California Inhibidores de la actividad de secuencias inmunoestimulatorias de adn.
EP1872786A1 (en) * 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
ATE356630T1 (de) * 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
DE69927495T2 (de) * 1998-05-14 2006-07-06 Coley Pharmaceutical Group, Inc., Wellesley Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
WO2001062207A2 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo

Similar Documents

Publication Publication Date Title
JP2003526673A5 (ja)
JP2003535043A5 (ja)
JP2003526670A5 (ja)
JP2003526672A5 (ja)
JP2003526662A5 (ja)
JP2004509061A5 (ja)
Gallichan et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract
US7528223B2 (en) Antigens encoded by alternative reading frames from pathogenic viruses
CA2402268A1 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
JP2004534769A5 (ja)
RU2002120922A (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
JP2000044490A (ja) アクリル型ポリマ―の崩壊剤としての使用
CZ302811B6 (cs) Vakcinacní prostredek
JP2003509473A (ja) ワクチン
CA2402247A1 (en) Biodegradable immunomodulatory formulations and methods for use thereof
JP2004506020A (ja) 経口投与固形ワクチン
JP2003507040A5 (ja)
JP2019537555A5 (ja)
JP2002524532A5 (ja)
JP2006502228A5 (ja)
Savoca et al. CO 2 laser vaporization as primary therapy for human papillomavirus lesions: A prospective observational study
JP2003514025A5 (ja)
EP1352955A3 (en) HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
JP2007504268A5 (ja)
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy